Friday, 16 October 2026European Markets

BEVER HOLDING Stock Bearish Momentum With A 27% Drop In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of BEVER HOLDING (AEX-Index: BEVER.AS) dropped by a staggering 27.37% in 21 sessions from €3.8 to €2.76 at 17:07 EST on Tuesday, after five successive sessions in a row of losses. AEX-Index is sliding 0.11% to €766.80, after five successive sessions in a row of gains.

BEVER HOLDING's last close was €2.76, 35.81% under its 52-week high of €4.30.

About BEVER HOLDING

Bever Holding NV operates as a real estate company in the Netherlands and Belgium. It develops apartments, commercial spaces, and hotels. The company also invests in, acquires, and leases real estate properties. Bever Holding NV was incorporated in 1975 and is based in Wassenaar, the Netherlands.

Earnings Per Share

As for profitability, BEVER HOLDING has a trailing twelve months EPS of €-0.91.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -22.1%.

Volume

Today's last reported volume for BEVER HOLDING is 5889 which is 4807.5% above its average volume of 120.

Yearly Top and Bottom Value

BEVER HOLDING's stock is valued at €2.76 at 17:07 EST, below its 52-week low of €2.76.

Moving Average

BEVER HOLDING's worth is way below its 50-day moving average of €3.66 and way below its 200-day moving average of €3.70.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BEVER HOLDING's stock is considered to be overbought (>=80).

More news about BEVER HOLDING (BEVER.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com